| Paris | |
| 47 | |
| Specialized in cardiovascular diseases. It is developing a new class of centrally acting drugs, called Brain Aminopeptidase A Inhibitors (BAPAIs), for the treatment of complicated/resistant hypertension and heart failure. | |
| The most advanced product is QGC001, a first in class antihypertensive drug-candidate for monotherapy, which started phase IIa at the beginning of 2015. More than 50% of patients have been recruited as of September 2015 and this clinical trial should be completed by June 2016. QGC001 inhibits an enzyme in the brain, generating a triple mechanism of action: - Reduction of vasopressin release, which increases the diuresis - Decrease of the sympathetic nerve activity, which lowers vascular resistance - Increase of the baroreflex, which controls heart rate Each of these actions contributes to the reduction of blood pressure. |
|
| SEGARD Lionel | |
| www.quantum-genomics.com | |
| ALQGC:FP |
Fiche créée le 10/04/2016 par 
Guillaume vue 6 fois.